5. Sharon D, Cathelin S, Mirali S, et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019;11(516):eaax2863.6. Eide CA, Kurtz SE, Kaempf A, et al. Simultaneous kinase inhibition with i...
维奈托克(venetoclax) 氮杂胞苷(Azacitidine) 多西环素(doxycycline) 维奈托克作为治疗AML白血病的特异性BCL-2抑制剂,对AML有很好的治疗作用,但是它作为单药或与诸如氮杂胞苷之类的低甲基化剂(hypomethylating agent, HMA)联用的临床疗效受到固有耐药性(intrinsic resistance)和获得性耐药(acquired resistance)的阻碍。 在...
Courtney D. DiNardo, MD, MSCE, provided an overview of venetoclax resistance and interrelated mechanisms, with a spotlight on kinase signaling pathways, TP53 mutation, monocytic, and other forms of resistance.
随着人类对血液系统恶性增殖性疾病认识的深入,克隆演化理论逐渐被接受和认可,用于分析认识各种血液系统疾病。其中,急性髓系白血病(AML)作为一种典型的经历克隆演化发展而来的恶性髓系血液系统疾病,其患者临床结局仍有待进一步改善。因此,了解其发生、发展及其接受治疗后的克隆...
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. Article CAS PubMed PubMed Central Google Scholar Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer ...
Consistent with known venetoclax resistance mechanisms, high levels of MCL-1 expression were found in patients who relapsed following FLAG-Ida + venetoclax [10]. The updated data of 62 patients (27 with ND AML and 35 with R/R AML) from the trial was recently presented. The ORR was ...
Venetoclax Erba was skeptical that the positive results in the older subgroup would be sufficient for approval, although he stated that even a small improvement would be beneficial in relapsed or refractory disease. “You can argue that the improvement of survival at 2 and 3 years of about 6% ...
This subset of AML happens to be enriched for characteristics associated with resistance to venetoclax. For example, a significant percentage of these types of patients have monocytic-type AML, which is a type of AML that does not respond as well to frontline venetoclax and azacitidine. What is...
BH3模拟物ABT-199 (Venetoclax,GDC-0199)是Bcl-2的选择性抑制剂。ABT-199是通过ABT-263优化而来,具有更好的选择性,不抑制Bcl-Xl。ABT-263因会抑制Bcl-Xl,可能导致血小板减少,临床应用受限。ABT-199目前已经进入3期临床试验。 然而...
Venetoclax, a BCL2 inhibitor, combined with azacitidine increased response rates, which were rapid and 70.1.3 First-Line Treatment durable, and improved survival and quality of life compared with azacitidine alone (DiNardo et al. Achieving and maintaining a first CR is crucial in 2020). As...